The registrational TACTI-004 trial in first line non-small cell lung cancer (1L NSCLC) has enrolled 378 patients globally, 50% of the trial's ...

In this phase 2 study, researchers explored whether fecal microbiota transplant could overcome resistance to immune checkpoint inhibition.

Patients should be selected for treatment based on the presence of an NRG1 gene fusion in tumor specimens. The Food and Drug Administration (FDA) has granted accelerated approval to Bizengri ® ...

Researchers have mapped lung cancer "neighborhoods", finding that cell metabolism is key for determining immunotherapy ...

A retrospective study finds that more than one third of patients with stage I-IIIA non-small cell lung cancer do not undergo ...

The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...

A meta-analysis of more than 20 phase 3 trials found no clear survival differences by sex or age in metastatic NSCLC but ...

Ocean Biomedical has announced promising research findings on its cancer immunotherapy candidates, which can enhance the effectiveness of tyrosine kinase inhibitors (TKIs) like osimertinib for ...

Ivonescimab's BLA acceptance is a milestone for PD-1/VEGF bispecific antibodies in the U.S., potentially transforming ...

Researchers headed by a team at Keck Medicine of USC have found that corticosteroids, which are commonly prescribed to non-small cell lung cancer (NSCLC) patients to alleviate cancer-related symptoms, ...